From: Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
 | High | Intermediate | Low | |||
---|---|---|---|---|---|---|
HR | P value | HR | P value | HR | P value | |
All (2004–2009) |  |  |  |  |  |  |
 Chemotherapy (yes vs no/unknown) | 0.60 (0.47, 0.77) | 7.40E−05 | 0.74 (0.62, 0.87) | 2.70E−04 | 0.90 (0.7, 1.15) | 0.40 |
 Radiation (yes vs no/unknown) | 1.22 (0.95, 1.56) | 0.12 | 0.72 (0.62, 0.83) | 1.40E−05 | 0.76 (0.65, 0.88) | 2.00E−04 |
 Age (old vs young) | 1.87 (1.37, 2.55) | 7.50E−05 | 2.39 (1.94, 2.93) | 9.36E−17 | 3.42 (2.75, 4.27) | 1.05E−27 |
 Stage (Stage I as baseline) |  |  |  |  |  |  |
  Stage II | 1.77 (1.35, 2.31) | 3.00E−05 | 1.7 (1.43, 2.02) | 3.00E−09 | 1.53 (1.29, 1.82) | 1.10E−06 |
  Stage III | 3.42 (1.62, 7.25) | 1.30E−03 | 4.59 (2.67, 7.88) | 3.40E−08 | 2.91 (1.39, 6.08) | 4.54E−03 |
  Stage IV | 6.68 (2.70, 16.53) | 4.00E−05 | 9.43 (4.86, 18.31) | 3.30E−11 | 21.58 (8.84, 52.64) | 1.50E−11 |
 Grade (Grade I as baseline) |  |  |  |  |  |  |
  Grade II | 1.26 (0.67, 2.34) | 0.47 | 1.29 (1.05, 1.58) | 0.01 | 1.34 (1.14, 1.58) | 4.10E−04 |
  Grade III | 1.38 (0.75, 2.54) | 0.30 | 1.85 (1.47, 2.32) | 1.40E−07 | 1.28 (0.98, 1.66) | 0.07 |
 Lymph node (+ vs −) | 1.8 (1.23, 2.64) | 2.30E−03 | 1.07 (0.82, 1.39) | 0.64 | 1.08 (0.83, 1.4) | 0.56 |
ER+HER2− (2010–2015) |  |  |  |  |  |  |
 Chemotherapy (yes vs no/unknown) | 0.62 (0.47, 0.82) | 7.70E−04 | 0.79 (0.66, 0.95) | 0.01 | 0.73 (0.52, 1.01) | 0.06 |
 Radiation (yes vs no/unknown) | 0.84 (0.64, 1.09) | 0.19 | 0.7 (0.59, 0.83) | 3.30E−05 | 0.77 (0.66, 0.89) | 4.20E−04 |
 Age (old vs young) | 1.37 (0.98, 1.93) | 0.07 | 2.69 (2.07, 3.5) | 1.70E−13 | 3.71 (2.85, 4.82) | 1.17E−22 |
 Stage (Stage I as baseline) |  |  |  |  |  |  |
  Stage II | 1.56 (1.15, 2.11) | 3.97E−03 | 1.44 (1.17, 1.77) | 6.60E−04 | 1.48 (1.24, 1.77) | 2.10E−05 |
  Stage III | 5.60 (3.05, 10.29) | 2.60E−08 | 2.44 (1.45, 4.11) | 7.70E−04 | 2.86 (1.77, 4.61) | 1.70E−05 |
  Stage IV | 11.59 (5.82, 23.07) | 3.10E−12 | 19.49 (10.76, 35.28) | 1.03E−27 | 14.44 (7.36, 28.33) | 8.10E−15 |
 Grade (Grade I as baseline) |  |  |  |  |  |  |
  Grade II | 1.83 (0.74, 4.53) | 0.19 | 1.13 (0.9, 1.42) | 0.29 | 1.1 (0.94, 1.3) | 0.24 |
  Grade III | 1.99 (0.81, 4.85) | 0.13 | 1.86 (1.45, 2.39) | 1.10E−06 | 1.31 (1.01, 1.69) | 0.05 |
 Lymph node (+ vs −) | 1.37 (0.97, 1.93) | 0.08 | 1.41 (1.11, 1.79) | 4.88E−03 | 1.06 (0.85, 1.32) | 0.59 |
ER+HER2+ (2010–2015) |  |  |  |  |  |  |
 Chemotherapy (yes vs no/unknown) | 0.48 (0.19, 1.25) | 0.13 | 0.5 (0.15, 1.66) | 0.26 | 0.61 (0.13, 2.81) | 0.53 |
 Radiation (yes vs no/unknown) | 0.68 (0.26, 1.76) | 0.42 | 0.33 (0.1, 1.08) | 0.07 | 0.61 (0.21, 1.77) | 0.37 |
 Age (old vs young) | 3.75 (0.5, 28.38) | 0.20 | NA | NA | NA | NA |
 Stage (Stage I as baseline) |  |  |  |  |  |  |
  Stage II | 1.28 (0.45, 3.59) | 0.64 | 0.33 (0.04, 2.64) | 0.30 | 0.69 (0.15, 3.19) | 0.63 |
  Stage III | 2.55 (0.23, 28.81) | 0.45 | 0 (0, Inf) | 1.00 | 0 (0, Inf) | 1.00 |
  Stage IV | 7.08 (0.68, 73.70) | 0.10 | NA | NA | 0 (0, Inf) | 1.00 |
 Grade (Grade I as baseline) |  |  |  |  |  |  |
  Grade II | NA | NA | 3.32 (0.41, 26.98) | 0.26 | 1.04 (0.32, 3.42) | 0.95 |
  Grade III | NA | NA | 3.62 (0.4, 33.04) | 0.25 | 0.75 (0.08, 6.82) | 0.80 |
 Lymph node (+ vs −) | 1.03 (0.26, 4.13) | 0.96 | 4.26 (0.38, 47.95) | 0.24 | 1.33 (0.18, 9.81) | 0.78 |